Guy Brusselle

Head of Department

Ghent University Hospital

Belgium

Research Interests

Explore related searches

Professors in Belgium

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Guy Brusselle is the Head of Department at Ghent University Hospital, Belgium. His research focuses on respiratory diseases, particularly asthma and chronic obstructive pulmonary disease (COPD), as evidenced by his recent publications on the burden of Respiratory Syncytial Virus, genetic and environmental risk factors for asthma, and clinical responses to therapies for severe asthma. He is actively involved in studies examining prognostic factors, treatment adherence, and innovative therapeutic approaches in respiratory care.

Articles (16)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (15)

Ken Bracke

Associate Professor

Ghent University

BELGIUM

Guy Brusselle

Research Interests

Explore related searches

Contact this professor

About

Articles (16)

Burden of Respiratory Syncytial Virus Disease in Adults with Asthma and Chronic Obstructive Pulmonary Disease: A Systematic Literature Review

Inflammatory and clinical risk factors for asthma attacks (ORACLE2): a patient-level meta-analysis of control groups of 22 randomised trials

Genetic and environmental risk factors for asthma: towards prevention

Preserved ratio impaired spirometry (PRISm): prognostic, preventable and treatable?

Patient-centred composite scores as tools for assessment of response to biological therapy for paediatric and adult severe asthma

Need for sex-stratified reference values for exhaled nitric oxide as biomarker in chronic cough

Clinical course of suspected familial and sporadic idiopathic pulmonary fibrosis: Data from the PROOF‐Next registry

Evaluating β2-agonists as siRNA delivery adjuvants for pulmonary surfactant-coated nanogel inhalation therapy

Clinical response and on-treatment clinical remission with tezepelumab in a broad population of patients with severe, uncontrolled asthma: results over 2 years from the NAVIGATOR and DESTINATION studies

Oral corticosteroid use and sarcopenia-related traits in older people with chronic airway disease: a population-based study

Evolving to a single inhaler extrafine LABA/LAMA/ICS – Inhalation technique and adherence at the heart of COPD patient care (TRIVOLVE)

European Respiratory Society Short Guidelines for the use of as-needed ICS/formoterol in mild Asthma

Long-term efficacy of dupilumab in severe asthma by baseline oral corticosteroid dose

Mepolizumab attenuates ILC2s proliferation and activity in adults with severe eosinophilic asthma

Reply to Lipworth and Chan

Is Efficacy of Tezepelumab Independent of Severe Asthma Phenotype?

Collaborators (15)

Ken Bracke

Apostolos Bossios

Lies Lahousse

Richard Beasley

Gernot Rohde

Tania Maes

Katharine Pike

Erik Melén

Clare Murray

Jo Hardy

Fernando Rivadeneira

ALBERTO PAPI

Mika Mäkelä

Sara R. A. Wijnant

Eef Vanderhelst

Make your next move.